Pediatric Grand Rounds Evaluation 2/24/21 (MOC) Title: “New Developments in Car T Cell Therapy"Speaker(s):Shannon Maude, MD, PhDAssistant Professor of PediatricsChildren’s Hospital of PhiladelphiaLearning Objectives:1. Identify the most common toxicities of CAR T cell therapies2. Describe the efficacy and mechanisms of failure of CAR T cell therapies3. Identify limitations of CAR T cell therapy in AML and solid tumors Question Title * 1. Date of Presentation Question Title * 2. Your First and Last Name: Question Title * 3. Your Email Address: Question Title * 4. Month and Day of your Birth Month: Day: Question Title * 5. Your Professional Category MD PhD PA NP RN Other (please specify) Question Title * 6. Please rate the impact of the following course objectivesAs a result of attending this activity, I am better able to: Strongly Agree Agree Disagree Strongly Disagree 1. Identify the most common toxicities of CAR T cell therapies 1. Identify the most common toxicities of CAR T cell therapies Strongly Agree 1. Identify the most common toxicities of CAR T cell therapies Agree 1. Identify the most common toxicities of CAR T cell therapies Disagree 1. Identify the most common toxicities of CAR T cell therapies Strongly Disagree 2. Describe the efficacy and mechanisms of failure of CAR T cell therapies 2. Describe the efficacy and mechanisms of failure of CAR T cell therapies Strongly Agree 2. Describe the efficacy and mechanisms of failure of CAR T cell therapies Agree 2. Describe the efficacy and mechanisms of failure of CAR T cell therapies Disagree 2. Describe the efficacy and mechanisms of failure of CAR T cell therapies Strongly Disagree 3. Identify limitations of CAR T cell therapy in AML and solid tumors 3. Identify limitations of CAR T cell therapy in AML and solid tumors Strongly Agree 3. Identify limitations of CAR T cell therapy in AML and solid tumors Agree 3. Identify limitations of CAR T cell therapy in AML and solid tumors Disagree 3. Identify limitations of CAR T cell therapy in AML and solid tumors Strongly Disagree Question Title * 7. Please rate the projected impact of this activity on your knowledge, competence, performance, and patient outcomes.*Competence is defined as the ability to apply knowledge, skills and judgement in practice (knowing how to do something) Yes No No Change The activity increased my knowledge The activity increased my knowledge Yes The activity increased my knowledge No The activity increased my knowledge No Change The activity increased my competence The activity increased my competence Yes The activity increased my competence No The activity increased my competence No Change The activity improved/will improve my performance The activity improved/will improve my performance Yes The activity improved/will improve my performance No The activity improved/will improve my performance No Change The activity will improve my patient outcome The activity will improve my patient outcome Yes The activity will improve my patient outcome No The activity will improve my patient outcome No Change If you answer "yes" to any of the items above, please describe: Question Title * 8. Please rate the speaker on knowledge/content of the presentation Excellent Above Average Average Below Average Poor Rating: Rating: Excellent Rating: Above Average Rating: Average Rating: Below Average Rating: Poor Comments: Question Title * 9. Do you feel this activity was free of commercial bias or influence?*Commercial bias is defined as a personal judgment in favor of specific product or service of a commercial interest Yes No (please explain) Comment: Question Title * 10. Do you feel this activity was evidence-based? Yes No (please explain) Comment: Question Title * 11. Do you plan to make changes to your practice as a result of attending this activity? Yes No (please explain) N/A (I do not work with patients) If yes, please explain with examples. If no, please indicate any perceived barriers to implementing changes. Question Title * 12. Please list suggestions you have for future topics as well as any addition comments. Question Title * 13. Are you claiming MOC credit? Yes No If you are not requesting MOC, please scroll to the end of the survey. Otherwise, please check the following attestation and provide your ABP ID number below: Question Title * 14. "I give permission to the University of Rochester to share my MOC completion data with the Accreditation Council for Continuing Medical Education (ACCME) and the American Board of Pediatrics (ABP) and transmit the completion data to the ACCME's PARS System on my behalf." Yes No Question Title * 15. Your ABP ID Number: In order to receive MOC credit for Grand Rounds, please fill out the correct answers to the two questions below. Credit will be awarded when one of the two questions have been answered correctly. Question Title * 16. What is the most common toxicity associated with CD19-directed CAR T cell therapies? 1) Tumor lysis syndrome 2) Cytokine release syndrome 3) Pancytopenia Question Title * 17. Which of the following is a mechanism of failure of CD19-directed CAR T cell therapies? Short CAR T cell persistence Antigen escape Both AccreditationThe University of Rochester School of Medicine and Dentistry is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physiciansCertificationThe University of Rochester School of Medicine and Dentistry designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Maintenance of Certification(MOC)Successful completion of this CME activity, which includes participation in the activity and individual assessment of and feedback to the learner, enables the learner to earn up to 1 MOC point in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit. Done